Astellas to end US Vesicare pact with GSK
This article was originally published in Scrip
Executive Summary
Astellas has exercised an option to end early an agreement with GlaxoSmithKline for the US co-promotion of the overactive bladder (OAB) therapy Vesicare (solifenacin succinate).